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Abstract
Background: Information on the health-related quality of life (HRQoL) of patients with genital warts (GW) in
populations in mainland China is still limited. The aim of the study was to use a generic instrument to measure the
impact of genital warts on HRQoL in men and women in this setting.
Methods: A multi-centre hospital-based cross-sectional study across 18 centers in China was conducted to
interview patients using the European quality of life-5 dimension (EQ-5D) instrument; respondents’ demographic
and clinical data were also collected.
Results: A total of 1,358 GW patients (612 men, 746 women) were included in the analysis, with a mean age of
32.0 ± 10.6 years. 56.4% of the patients reported some problems in the dimension of Anxiety/Depression (highest),
followed by Pain/Discomfort (24.7%) and Mobility (3.5%). The overall visual analogue scale (VAS) score of the study
population was found to be 65.2 ± 22.0, and the EQ-5D index score was found to be 0.843 ± 0.129 using Japanese
preference weights (the Chinese preference was unavailable yet). Patients with lower VAS means and EQ-5D index
scores were more often female, living in urban area, and suffering multiple GW (all p values < 0.05), but the values
did not differ notably by age (p values > 0.05).
Conclusions: The HRQoL of patients with GW was substantially lower, compared to a national representative
general population in China (VAS = ~80); the findings of different subgroups are informative for future GW
prevention and control efforts.
Background
Genital warts (GW) is one of the most common sexually
transmitted diseases and about 90% of GW are caused
by infection with human papillomavirus (HPV)-6 and
HPV-11 [1]. The incidence of GW is increasing globally
although some developed countries, such as US and
Australia, have reported relatively low rates ( < 0.3%)
[ 2 , 3 ] .I n f o r m a t i o no nt h ed i s e a s eb u r d e no fG Wi n
mainland China is still limited, but a relatively higher
GW prevalence (0.5%) was reported in general popula-
tions of other Asian regions (including India, Taiwan
and Hong Kong) [1]. However, the variability in the GW
prevalence among different data sources from other Asia
Pacific countries might suggest that under-reporting
potentially existed in the population surveillance systems
[1]. In addition, a high post-treatment recurrence rate of
GW has been reported (40%) [4] and this characteristic
of GW imposes a considerable sociopsychological bur-
den (such as worries and concerns, negative emotional
and sexual impact, shame or stigma, and worse interac-
tions with partner and/or doctors [5,6]) and economic
burden [7] on the patients.
It has been estimated that multivalent prophylactic
HPV vaccine has the potential to protect up to 83% of
genital warts or condylomata acuminate in mainland
China [8]. In an era of HPV vaccination, a number of
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vaccines have been performed globally. Health related
quality of life (HRQoL) contains self-reported measures
of physical and psychological aspects, and an accurate
impact analysis of genital warts on HRQoL was expected
to contribute to the health economic evaluation on
(HPV) vaccines protects against related HPV types. The
extent of HRQoL of patients with GW has previously
been quantified in different settings using generic instru-
ments [6,9-11], including the European quality of life-5
dimension (EQ-5D) measure. EQ-5D is a standardized
and commonly used instrument on HRQoL [12], and is
also one of only a few measures recommended for use
in cost-effectiveness analysis [13,14]. However, most of
the quality of life studies using EQ-5D in China’s popu-
lations were more focused on the general populations or
patients with various chronic diseases [15-18], and
assessment related to GW in this setting has not been
performed.
The Cancer Foundation of China (CFC) and the Can-
cer Institute of Chinese Academy of Medical Sciences
(CICAMS) jointly conducted a multi-centre hospital-
based epidemiological and economic study on genital
w a r t sa c r o s sC h i n a .A sp a r to ft h i sb r o a dp r o j e c t ,t h e
current study’s aim was to use the generic instrument
EQ-5D to measure the impact of genital warts on health
related quality of life in men and women in mainland
China.
Methods
From July 2007 to July 2008, patients with genital warts
were enrolled in 18 selected centers across seven geo-
graphic regions of China (Northeast, North, Northwest,
Central, Southwest, South and East China). Generally,
within each region, one province-level centre in a more
developed area, and one county-level centre in a less
developed area were selected. In addition, four addi-
tional study sites were selected from the North and East
China regions in order to provide more information on
more developed areas or metropolitan cities. Thus, a
total of 11 higher level centers and 7 lower level centers
eventually participated in the current survey (Figure 1).
A total of 100 GW patients were initially required for
each centre at a higher level and 50 patients at a lower
level, and a convenience sampling method was applied
within each centre. Patients who were currently diag-
nosed with genital warts, aged 18 years or older and
provided informed consent (no participation fee applied)
were eligible for this study regardless of their gender or
whether they were an incident or recurrent case. Central
institutional review board approval was obtained from
the Cancer Foundation of China.
The EQ-5D instrument has several language versions
and has been applied to a wide variety of populations
and diseases [12], and promising evidence for the mea-
surement equivalence of EQ-5D’s English and Chinese
versions has been reported [19]. EQ-5D contains five
dimensions measurement, including Mobility, Self-care,
Activities, Pain/Discomfort and Anxiety/Depression [12].
Three options are listed for each dimension: whether
the subject has no problem, a moderate problem or an
extreme problem. Separately, EQ-5D instrument also
contains a visual analogue scale (VAS) which allows the
study subjects themselves to assess and self-record their
health status from 0 (the worst) to 100 (the best) [12].
Using the EQ-5D instrument (Chinese version), a face-
to-face interview was administrated by a project staff
member, or alternatively a capable patient completed
the questionnaire by him or herself in the presence of a
trained interviewer who answered any questions the par-
ticipants had about the questionnaire. In addition,
further patient information including place of residence,
education, income, marriage status, whether or not the
patient is a smoker, sexual behavior and clinical charac-
teristics were also collected. Information from patients
who did not accept the invitation was not recorded in
the study.
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Figure 1 The distribution of study sites in China. The 11 higher
level centers included Beijing (2 centers), Tianjin, Shenyang
(Liaoning Province), Xi’an (Shaaxi Province), Changsha (Hunan
Province), Chongqing, Shenzhen (Guangdong Province), Shanghai,
Nanjing (Jiangsu Province) and Fuzhou (Fujian Province). The seven
lower level centers included Dashiqiao County (Liaoning Province),
Hetian County (Xinjiang Autonomous Region), Xinmi Prefecture
(county-level, Henan Province), Panyu/Conghua County (Guangdong
Province), Tonggu County (Jiangxi Province), Yangcheng County
and Changzhi Prefecture (Shanxi Province). Data related to the less-
developed centre in Southwest China were not available. Most of
the study hospitals have had well established collaboration with
CICAMS on a number of prior studies associated with HPV and
cervical cancer.
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ducted in three sites (urban: Beijing; rural: Shanxi and
Jiangxi); the initial study flowchart and questionnaire
contents (excluding the EQ-5D questionnaire) were then
modified and optimized based on the feedback from the
pilot study. An investigators’ meeting was then organized
by CICAMS and CFC to provide data collection training
and to introduce the study protocol and an operations
manual to all the co-principle investigators and the main
project members from 18 sites. The meeting participants
were then required to provide training to other project
team members (including nurses and physicians at the
clinics) in local individual centers, based on the study
operation manual. The operations manual contained
questionnaire instructions, coding, quality control pro-
cess, collaborators’ responsibility, logistic instructions
and other details in an operational level. CICAMS was
responsible for all database building, logistical data
checks (by interacting with local staff) and data analysis.
Data collection and double entry and basic data checks
were conducted in the 18 collaborative centers/hospitals.
The characteristics of the study population were
described in general terms. Percentages of patients
reporting any problems, age-specific means of EQ-5D
VAS scores and their 95% confidence intervals were
analyzed (overall and by sex), using Chi-square test or
one-way ANOVA approach. Because of the absence of a
EQ-5D preference weight set for the Chinese popula-
tion, we applied the preference weight sets from other
populations (the UK, US and Japan) [20-22] to estimate
the mean EQ-5D index score of this GW population in
China. Detailed VAS means and EQ-5D index scores by
population characteristics were calculated and a one-
way ANOVA approach was applied to detect the statis-
tical differences between subgroups. In addition, Pearson
correlation among VAS means and EQ-5D index scores
using the three preference weight sets were character-
ized using a univariate linear regression model. Since a
very high association between weighted and non-
weighted EQ scores has been reported [23], we then
conducted a multivariate linear regression analysis to
check the robustness of important variables, by input-
ting variables with statistical significance confirmed in
the non-weighted analysis. For the ordinary unordered
categorical variables with more than two subgroups,
dummy variables were applied and the subgroup with
lowest mean/score (which was southwest in the region
category and recurrent GW in the clinical status cate-
gory) was chosen as the reference subgroup. All analysis
used two tailed tests.
Results
A total of 1,358 outpatients with genital warts were
included in the analysis (612 men and 746 women),
with a mean age of 32.0 years (SD: 10.6, range: 18-86).
Of all study patients, 75.1% of them were enrolled from
urban-based hospitals, 33.2% received college or higher
education, 30.0% held health insurance, 22.2% were cur-
rent frequent smokers, and their median monthly
income was 1,400 Chinese Yuan (~200 US$). In addi-
tion, 69.3% of the study subjects were married or living
with their partners, and 54.3% have had two or more
lifetime sexual partners. During the survey, the patients
were basically categorized into three clinical statuses,
including the initial clinical visit for GW, the follow-up
v i s i tw i t h i na ne p i s o d e ,a n dv i s i t sf o rr e c u r r e n tG W ,
with the proportions in each status being 76.0%, 10.8%
and 13.3%, respectively. In all, 26.2% of the subjects
were observed to have a single genital wart on their
bodies, while the rest suffered multiple genital warts.
Table 1 illustrates the results of the five study dimen-
sions. For the whole study population, the dimension of
Anxiety/Depression had the highest rate of self-reported
problems (56.4%), followed by Pain/Discomfort (24.7%),
Mobility (3.5%), Usual activities (2.8%) and Self-care
(0.5%). Compared to the male patients, females tended
to report more problems in three dimensions, including
Anxiety/Depression (50.1% vs. 61.5%), Pain/Discomfort
(20.6% vs. 28.0%), and Mobility (1.3% vs. 5.2%) (all P
values < 0.005). The overall VAS mean among all cases
was 65.2 (SD: 22.0), and men had a higher mean score
than women (69.0 vs. 62.1, P < 0.001). To make com-
parisons for all of the reported groups, relevant findings
from a national population-based survey in China [15]
were also added to Table 1 as references. After applying
the preference weights of the Japanese, UK and US
populations, the overall EQ-5D index scores of the cur-
rent analysis were 0.843, 0.826 and 0.859, respectively;
and similarly, men scored higher than women under
every one of the three preference weight sets (all P
values < 0.001) (Table 2).
A range of strengths of correlation between results
from different analyses were characterized. On one
hand, relatively low Pearson correlations R between EQ
VAS mean and EQ-5D index scores were observed
(0.371, 0.423, 0.412 using Japanese, UK and US prefer-
ence weights respectively, all p values < 0.001). On the
other hand, unsurprisingly, a slightly higher agreement
(0.984, p < 0.001) was observed between EQ-5D index
scores of UK and US preference weights compared to
those of the other two pairs (Japan & UK: 0.817, Japan
& US: 0.860, all p values < 0.001); this situation is
potentially due to the cultural dissimilarity between
W e s t e r na n dA s i a np o p u l a t i o n s .I na d d i t i o nt ot h i s ,
compared to the EQ-5D results for populations in the
UK and US, the reported percentages of subjects’ pro-
blems by each of the EQ-5D’s five dimensions among
the Japanese general population were closer to those of
Shi et al. BMC Public Health 2012, 12:153
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only the preference weight set of the Japanese popula-
tion was applied when we calculated further characteris-
tic-specific EQ-5D index scores in this analysis.
Table 3 presents further detailed mean VAS and EQ-5D
index scores for different subgroups. Briefly, female
patients, living in urban areas, residing in the Southwest
region, smoking less frequently and with multiple clini-
cally-confirmed GW were statistically associated with
lower VAS and EQ-5D index scores (one-way ANOVA
results, all p values < 0.05); and a lower monthly income
and the situation of recurrent GW probably contributed to
aw o r s eH R Q o Lo fG Wp a t i e n t s( P <0 . 0 5i nt h eE Q - 5 D
index score calculation, but P > 0.05 in the VAS analysis).
Significant differences were not detected among subgroups
by age (Figure 2), marital status, education, insurance or
the number of lifetime sexual partners (all P values > 0.05).
In the multivariate linear regression analysis, similar
results were observed (Table 4); when using the VAS
mean as the dependent variable, the variables of gender,
rural or urban, residence in the North or Central regions
of China, and single/multiple GW were retained in the
final model (all P values < 0.01, adjusted R square =
0.065). When placing EQ-5D index score as the dependent
variable, more factors entered the model, including initi-
ally occurred GW, monthly income, region of East, and
region of Northeast (all P values < 0.001, adjusted R square
= 0.117) (Table 4). The factors of smoking and monthly
income were not statistically associated with the HRQoL
of GW patients in the multivariate analysis.
Table 1 Percentages of subjects self-reported problems and means of visual analogue scale (VAS), total and by sex
EQ-5D dimension The current study Findings from a national population-based survey in China, 2008
[15]
Male Female Total Male Female Total*
No. %N o . %N o . % % (N = 58,163) % (N = 62,540) % (N = 120,703)
Mobility
No 604 98.7 707 94.8 1,311 96.5 95.7 94.6 95.1
Moderate 8 1.3 38 5.1 46 3.4 4.0 5.0 4.5
Extreme 0 0.0 1 0.1 1 0.1 0.3 0.4 0.4
Self-care
No 610 99.7 741 99.3 1,351 99.5 97.3 96.6 96.9
Moderate 2 0.3 5 0.7 7 0.5 2.3 3.0 2.7
Extreme 0 0.0 0 0.0 0 0.0 0.4 0.4 0.4
Usual activities
No 596 97.4 723 96.9 1,319 97.1 96.0 94.9 95.4
Moderate 16 2.6 21 2.8 37 2.7 3.3 4.3 3.8
Extreme 0 0.0 2 0.3 2 0.1 0.7 0.8 0.8
Pain/Discomfort
No 486 79.4 537 72.0 1,023 75.3 92.8 89.5 91.1
Moderate 122 19.9 205 27.5 327 24.1 6.9 10.0 8.5
Extreme 4 0.7 4 0.5 8 0.6 0.3 0.5 0.4
Anxiety/Depression
No 305 49.8 287 38.5 592 43.6 94.8 92.9 93.8
Moderate 259 42.3 362 48.5 621 45.7 4.9 6.7 5.8
Extreme 48 7.8 97 13.0 145 10.7 0.3 0.4 0.4
VAS score
612 69.0 (mean) 746 62.1 (mean) 1,358 65.2 (mean) 80.9 (mean) 79.4 (mean) 80.1 (mean)
Chi-square tests were performed, female patients tended to report more problems in three dimensions, including Anxiety/Depression, Pain/Discomfort and
Mobility, when comparing to male patients (all P values < 0.005).
* The percentages of “Total” group were estimated based on the reported findings for males and females with considering each group’s sample size.
Table 2 The EQ-5D index score using different preference
weights, total and by sex
Preference weight set
applied
Male Female Total
Mean SD Mean SD Mean SD
Japan 0.864 0.13 0.827 0.126 0.843 0.129
UK 0.856 0.185 0.802 0.21 0.826 0.201
US 0.882 0.137 0.84 0.15 0.859 0.145
One-way ANOVA approach was applied to compare scores between men and
women
(all P values < 0.001)
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The current work is a unique large-scale multi-centre
study focusing on the HRQoL of male and female
patients with GW using a generic and internationally
comparable instrument, the EQ-5D. We found that
anxiety and depression posed a major problem for GW
patients, and the measurement of VAS suggested that
the HRQoL of GW patients was substantially lowered.
The current analysis using different preference weights
provided a range of utility estimates (overall and
Table 3 Mean visual analogue scale (VAS) and EQ-5D index score, by population characteristics*
Variable No. % VAS EQ-5D index score**
Mean SD Sig.
# Mean SD Sig.
#
Sex
Male 612 45.1 69.0 21.3 < 0.001 0.864 0.130 < 0.001
Female 746 54.9 62.1 22.1 0.827 0.126
Region
North 372 27.4 66.6 25.0 < 0.001 0.866 0.135 < 0.001
Northeast 128 9.4 64.0 24.7 0.897 0.125
Northwest 151 11.1 62.2 20.6 0.790 0.121
Central 133 9.8 72.3 12.8 0.871 0.120
Southwest 100 7.4 57.3 22.2 0.790 0.111
South 135 9.9 66.1 18.6 0.823 0.134
East 339 25.0 64.5 21.2 0.835 0.120
Setting
Urban 1,020 75.1 63.2 22.4 < 0.001 0.837 0.126 < 0.005
Rural 338 24.9 71.0 19.6 0.862 0.137
Be married / living together
Yes 941 69.3 65.0 22.2 > 0.05 0.844 0.130 > 0.05
No 417 30.7 65.5 21.6 0.843 0.128
Education
Middle school or lower 408 30.0 66.3 20.7 > 0.05 0.842 0.132 > 0.05
High school 499 36.7 66.1 22.0 0.843 0.130
College or above 451 33.2 63.2 23.1 0.845 0.127
Monthly income (Chinese Yuan) *
< 1000 364 26.8 63.5 22.4 > 0.05 0.827 0.133 < 0.005
1000~ 422 31.1 66.8 21.3 0.838 0.124
2000~ 223 16.4 65.8 22.8 0.852 0.131
3000~ 347 25.6 64.5 22.0 0.860 0.128
Any insurance coverage*
Yes 432 31.8 65.8 21.8 > 0.05 0.842 0.129 > 0.05
No 925 68.1 65.0 22.0 0.844 0.131
Frequently smoking
Yes 301 22.2 68.2 21.2 < 0.01 0.860 0.131 < 0.05
No 1,057 77.8 64.3 22.2 0.839 0.129
Number of lifetime sexual partners*
1 612 45.1 63.8 22.7 > 0.05 0.852 0.132 > 0.05
2 318 23.4 65.3 21.9 0.839 0.128
3 or more 421 31.0 67.0 21.0 0.834 0.126
Clinical status
First clinical visit for the initially occurred GW 1,032 76.0 65.7 21.8 > 0.05 0.853 0.129 < 0.001
Follow-up visit for the initially occurred GW 146 10.8 64.1 24.4 0.822 0.126
Recurrent GW 180 13.3 63.9 21.0 0.804 0.124
Single or multiple genital warts
Single 356 26.2 68.0 21.2 < 0.01 0.869 0.127 < 0.001
Multiple 1,002 73.8 64.2 22.2 0.835 0.129
* Some data missing; ** Japanese preference weights applied;
# One-way ANOVA analysis.
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related cost-effectiveness evaluations. This study also
determined the characteristics of patents with relatively
lower quality of life, including being female, living in
urban areas and suffering multiple GWs, which will be
informative for future GW prevention and control
efforts.
The research group has published a parallel work con-
ducted as another part of the whole GW project [5].
Both the studies explored the quality of life issue but
from different perspectives and each study had its own
emphasis. For example, firstly, the current study focused
on both males and females, while the previous work
mainly assessed female populations. Secondly, the cur-
rent study was very focused on GW patients only, but
the study by Wang et al included women who have a
spectrum of HPV-related health statuses or laboratory
diagnosis, including normal/abnormal pap smear, cervi-
cal precancer, and HPV+/- after abnormal pap, and
patients with GW were only one sub-group in the broad
analysis [5]. Thirdly, the previous work used a newly-
developed HPV-specific instrument, the HPV impact
profile (HIP); it is more sensitive and can recognize
some slight differences among the targeted HPV-related
s u b g r o u pw o m e n ,b u ti ti sm o r ed i f f i c u l tt od i r e c t l y
compare the findings of the HIP study and other quality
of life studies using different instruments. Differently,
the EQ-5D, used by the current analysis, is an easy-to-
compare HRQoL instrument and commonly-used world
w i d e l y[ 1 2 ] .F i n a l l y ,c o m p a r e dt ot h eH I Ps c o r eo u t -
comes, the EQ-5D index score outcomes reported by
the current study were relatively more convertible when
Table 4 Mean VAS and EQ-5D index score, by population characteristics, using a multivariate linear regression
approach
Variable Variable definition Unstandardized
Coefficients
Standardized Coefficients t Sig.
B SD Beta
VAS mean
Constant 63.721 1.455 43.795 0.000
Sex Woman = 0; Man = 1 7.451 1.176 0.168 6.335 0.000
Setting Rural = 0; Urban = 1 -6.459 1.361 -0.127 -4.747 0.000
Single/Multiple GW Multiple GW = 0; Single GW = 1 4.138 1.334 0.082 3.101 0.002
Region-Central Southwest = 0; Central = 1 8.653 2.042 0.117 4.237 0.000
Region-North Southwest = 0; North = 1 3.655 1.341 0.074 2.725 0.007
Region-East Southwest = 0; East = 1 0.032 0.010 0.108 3.145 0.002
EQ-5D index score*
Constant 0.748 0.012 61.166 0.000
Sex Woman = 0; Man = 1 0.035 0.007 0.134 5.140 0.000
Setting Rural = 0; Urban = 1 -0.032 0.008 -0.106 -3.933 0.000
Single/Multiple GW Multiple GW = 0; Single GW = 1 0.029 0.008 0.098 3.749 0.000
Region-Central Southwest = 0; Central = 1 0.067 0.013 0.153 5.332 0.000
Region-North Southwest = 0; North = 1 0.069 0.009 0.238 7.813 0.000
Region-East Southwest = 0; East = 1 0.038 0.009 0.127 4.188 0.000
Region-Northeast Southwest = 0; Northeast = 1 0.087 0.013 0.196 6.905 0.000
Clinical status- Recurrent GW Recurrent GW = 0; Initially occurred GW = 1 0.031 0.008 0.103 3.968 0.000
Monthly income (Chinese Yuan) < 1000 = 1; 1000 ~ = 2; 2000 ~ = 3; 3000 ~ = 4 0.012 0.003 0.107 4.040 0.000
* Japanese preference weights applied.
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> 0.05); * Japanese preference weights applied.
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as the study outcome.
The current analysis found that more than half of the
GW patients in this survey were suffering anxiety and
depression. This is a dramatically high proportion, when
compared to the value of < 7% of the sampled general
population (aged 15-49 years, by 5-year age group)
across mainland China, as a part of the Chinese
National Health Services Survey in 2008 (N = 120,703)
[15]; and the proportion is also higher than that of
some other countries (~ < 30%, pooled in a previous
s t u d yb yW a n ge ta l )[ 1 7 ]a n dag r o u po fG Wp a t i e n t s
in the UK (24%) [9]. This situation is due mainly to the
relatively conservative culture and attitude to sex in
China; being diagnosed with sexually transmitted dis-
eases such as GW could be regarded as a big humilia-
tion for patients and they usually would not let other
people know and would not receive support even from
their families. As expected,w ea l s of o u n dt h a tah i g h
proportion of study cases were feeling pain and discom-
fort (24.7%) when compared to the Chinese general
population ( < 10%, in patients aged 15-49 years) [15].
Providing questionnaire interview to part of the patients
after their treatment could increase the feeling of pain,
but the current study did not distinguish the ordering of
treatment and interview. However, discomfort is com-
monly feeling in GW patients, which could explain
some of this detriment. In contrast to the dimension of
Anxiety/Depression, the dimensions of Mobility, Self-
care and Usual Activities in this GW population are
generally less impacted when compared to local and
international general populations [15,17]; this situation
is due partly to the reality that most of the studied GW
patients (~93%) were younger than 50 years old, and
were able to move, to take care of themselves, and to
complete their usual activities with no difficulty. Also,
the situation of lower rates of any problems in the three
dimensions mentioned above is consistent with the find-
ings of a UK GW study [9].
A large-scale survey included EQ-5D instrument was
previously conducted based on a national representative
sample in China in 2008, where the average VAS were
found to be 80.9 for male and 79.4 for female [15].
S i n c eH R Q o Ls c o r e sa r ev e r ya g e - d e p e n d e n tb u tt h e
subjects of current study mainly aged 15-49 years, we
restricted the comparison to narrower age groups (15-
49 years, by 5-year age group); it was noted that the
national survey reported relatively higher values of VAS
score (81.4-89.8 for male, 79.2-89.6 for female). The
finding that the mean VAS scores in the current study
are lower than those of Chinese general population
(65.2 versus ~80 [15]) suggests that the HRQoL of
patients with GW is notably lower than that of the gen-
eral population. When compared to prior GW studies
using EQ-5D in other countries, the mean VAS scores
of the current Chinese GW cohort are lower than the
estimate of an Australian study (68.9, N = 40) and of a
UK study (72, N = 81) [6,9], but somewhat closer to the
estimate of a Canadian study (65.1, N = 39) [11]. The
observed differences between these GW cohorts in these
settings might be explained by the differences in the
VAS scores of the general populations behind them,
which are 82.5, 78.7 and 80.1 for the UK, Canada and
China, respectively. Based on results from other pub-
lished works [9,15,17], it is not surprising to see that
female GW patients had lower VAS scores than male
patients. Although a VAS score declining with age was
observed in a general population-based survey [15], our
age curve of VAS scores shows a flat pattern, which is
consistent with a prior UK GW study [9]. A potential
reason for this inconsistency is that the majority of the
GW patients were sexually active, and they might have a
lower probability of susceptibility to a range of ageing
diseases or situations.
Due to the absence of an EQ-5D preference weight set
in the Chinese population, three other populations’ pre-
ference sets were applied to estimate the EQ-5D index
scores in the current analysis. Our findings suggest that
scores based on the Japanese preference weights could
be regarded as the baseline utility values for future cost-
effectiveness evaluations, whilst the results based on the
UK and US populations could provide a plausible range
of utilities estimates for sensitivity analysis. When com-
paring our EQ-5D index scores to other international
G Ws t u d i e s ,aw i d ed i f f e r e n c ew a sn o t e db u ta l lo u r
EQ-5D index scores using varied populations preference
weights (0.826, 0.843 and 0.859) are within the range
(0.76 - 0.91) of the available data from other populations
[9-11]; the lowest utility value (0.76) of GW patients was
from a Canadian study, and the highest value (0.91) was
reported by Myers et al (conference abstract, details
unavailable) which has been cited by a number of more
recent cost-effectiveness evaluations of quadrivalent
HPV vaccine [24-27]. Our EQ-5D index scores analysis
also further supports the hypothesis that female patients
suffered a larger decrease in quality of life than males
and the scores did not differ notably among age groups,
as we previously discussed in the VAS scores analysis.
In addition to the variable of gender, other character-
istics could also potentially affect the HRQoL of GW
patients. Our finding that the urban patients suffered a
heavier physiological burden than rural patients could
be explained by the urban residents’ higher stress from
job and mortgage payments and living a faster-paced
life. This finding is identical with the results of another
HRQoL analysis of HPV-related lesions (including GW)
using a HPV-sensitive instrument [5]. It is not surpris-
ing to observe that subjects in Southwest China had the
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reported that the general population in Guizhou Pro-
vince in the Southwest region of China had a relatively
low HRQoL (VAS: ~68 - ~ 80 in residents aged 15-49
years) [18]. It is also understandable that more patients
with multiple genital warts reported lower scores than
patients with only single GW. Although most of the dif-
ferences detected between subgroups were marginally
less than the mean of clinically important differences in
EQ-5D (0.074) [28], they were still within the range
(0.011-0.140) [28], and could potentially generate a rela-
tively significant impact on mass public health interven-
tion programs. As for other variables marginally
associated with the HRQoL of GW patients, including
initial or recurrent GW, smoking, patient’sm o n t h l y
income and education level, they are beyond the scope
of the current discussion, and more research needs to
be done.
This analysis has some limitations. Firstly, selection
biases could occur in this study, due to the convenient
sampling approach we used; we also failed to collect
information of non-attended patients and thus could
not assess the differences in characteristics between the
study participants and those who declined to participate.
Secondly, use of the generic EQ-5D instrument, which
is not sensitive to HPV-related diseases, potentially
underestimates the negative impact from GW and a
ceiling effect could occur. Thirdly, the current study is a
questionnaire interview-based survey which is usually
sensitive to the capacities of the interviewers and quality
control, and some of the clinical physicians who admini-
strated the interview had not directly received training
provided by CICAMS, and quality-control could poten-
tially vary among study centers to some extent. Another
limitation of the study is that we did not have Chinese
population specific preference weights and thus could
not calculate the EQ-5D index scores accurately.
Furthermore, combined with further data related to
average duration of a clinical episode and the frequency
of recurrence of GW, the detailed utilities findings from
t h ec u r r e n ts t u d yw o u l db ei n f o r m a t i v ef o rf u t u r ec o s t -
effectiveness evaluations related to quality-adjusted life
years saved by new interventions against GW.
Conclusions
The HRQoL of patients with GW was substantially low-
ered when compared to the general population in main-
land China, and the quality of life was even worse
among some sub-groups. It is vital to strengthen the
public genital warts prevention program. In the era of
HPV vaccination, although prophylactic HPV vaccines
are not yet licensed in China, introducing a prophylactic
vaccine protecting against HPV-6 and -11 would be fea-
sible. Regarding the psychological effect of such an
intervention on GW patients, effectively reducing
patients’ anxiety and depression can have a remarkably
positive impact on the overall quality of life of GW
patients. In addition, particular attention should prob-
ably be given to female patients and patients from urban
areas and who are suffering worse clinical situations in
clinical practice.
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